![]() |
市場調查報告書
商品編碼
1722750
血氣和電解質分析儀市場報告(按產品類型(分析儀、耗材)、設備(台式、攜帶式)、最終用戶(醫院、診所、門診手術中心等)和地區)2025 年至 2033 年Blood Gas and Electrolyte Analyzer Market Report by Product Type (Analyzers, Consumables), Modality (Benchtop, Portable), End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region 2025-2033 |
2024年全球血氣和電解質分析儀市場規模達22億美元。展望未來, IMARC Group預計到2033年市場規模將達到37億美元,2025-2033年期間的成長率(CAGR)為5.37%。心血管併發症、癌症和糖尿病等各種慢性疾病的發病率不斷上升,先進技術的融合日益緊密以減小設備尺寸並提高準確性,以及即時診斷(POC)檢測服務的採用率不斷上升,這些都是推動市場成長的一些因素。
血氣電解質分析儀是指用於測量全血樣本中血氣(二氧化碳和氧氣的分壓)、pH值、電解質和代謝物等各種參數的醫療設備。它們被廣泛用於檢測代謝失衡以及測量腎臟和心臟功能。它們還有助於確定血液中異常的電解質水平、氧氣或二氧化碳交換水平以及患者的酸鹼平衡。此外,它們還有助於識別糖尿病、血管出血和藥物消耗。近年來,血液氣體和電解質分析儀因其易於使用、經濟高效、準確且快速出結果而在臨床診斷實驗室和重症監護室中廣受歡迎。
血氣和電解質分析儀可以簡化工作流程,最大限度地減少錯誤,只需最低限度的維護,並快速提供準確的結果。因此,重症監護室 (ICU)、手術室和急診室的患者數量的增加是推動市場成長的主要因素。除此之外,糖尿病和心血管疾病等慢性疾病的廣泛流行以及更容易患上這些疾病的老年人口的成長也增加了對產品的需求。此外,對高吞吐量、整合和自動化系統的需求也顯著增加。同時,血液氣體和電解質分析儀與實驗室資訊系統和電子病歷的日益融合,簡化了工作流程,並能夠有效監測患者的健康狀況,從而促進了市場的成長。此外,一些領先的公司正在大力投資開發易於使用和操作且維護要求最低的攜帶式血氣和電解質分析儀。其他因素,包括對即時檢驗 (POCT) 的偏好轉變、醫療保健行業的發展、技術進步、產品創新以及廣泛的研發 (R&D) 活動,也創造了良好的市場前景。
The global blood gas and electrolyte analyzer market size reached USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2033, exhibiting a growth rate (CAGR) of 5.37% during 2025-2033. The growing occurrence of various chronic illnesses like cardiovascular complications, cancer, and diabetes, increasing integration of advanced technologies to decrease the size of devices and enhance accuracy, and rising adoption of point-of-care (POC) testing services are some of the factors impelling the growth of the market.
Blood gas and electrolyte analyzers refer to medical devices used to measure various parameters, including blood gas (partial pressure of carbon dioxide and oxygen), pH, electrolytes, and metabolites, in a whole blood sample. They are widely utilized for the detection of metabolic imbalances and the measurement of renal and cardiac functions. They also help determine abnormal electrolyte levels in the blood, levels of oxygen or carbon dioxide exchange, and the acid-base balance of the patient. Moreover, they assist in identifying diabetes, blood vessel hemorrhage, and drug consumption. In recent years, blood gas and electrolyte analyzers have gained immense popularity across clinical diagnostic labs and critical care units due to their ease of use, cost-effectiveness, accuracy, and fast results.
Blood gas and electrolyte analyzers can streamline work processes, minimize errors, require minimum maintenance, and provide accurate results quickly. As a result, the increasing number of patients in intensive care units (ICUs), operating rooms, and emergency departments represent the primary factor driving the market growth. Besides this, the widespread prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the growing geriatric population that is more susceptible to developing these medical ailments are augmenting the product demand. Additionally, there has been a significant increase in the demand for high throughput, integrated, and automated systems. Along with this, the rising integration of blood gas and electrolyte analyzers with laboratory information systems and electronic medical records to streamline the workflow and enable effective monitoring of patient health is catalyzing the market growth. Furthermore, several leading players are making heavy investments for the development of portable blood gas and electrolyte analyzers with easy-to-use and handle features and minimum maintenance requirements. Other factors, including the shifting preferences toward point-of-care testing (POCT), developments in the healthcare industry, technological advancements, product innovations, and extensive research and development (R&D) activities, are also creating a favorable market outlook.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.